A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of iR2 (Ibrutinib Lenalidomide, Rituximab in Untreated and Unfit Elderly Patients With Diffuse Large B-cell Lymphoma
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 15 Feb 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2021.
- 15 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 17 May 2019 New trial record